Moderna, Inc. (NASDAQ: MRNA) saw its stock soar 5.33% in pre-market trading on Monday, as investors reacted positively to the company's announcement of its upcoming presentations at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress.
The biotechnology company revealed that it will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the prestigious conference in Vienna, Austria, from April 11-15, 2025. Moderna's strong presence at the event, with twelve scientific presentations including three oral presentations, demonstrates the breadth and depth of its research pipeline in respiratory and emerging infectious diseases.
The market's enthusiastic response to this news highlights the continued importance of Moderna's mRNA technology platform and its potential applications beyond COVID-19 vaccines. As the company strives to expand its portfolio and showcase its capabilities in addressing various infectious diseases, investors appear to be betting on Moderna's long-term growth prospects and its ability to maintain its position as a leader in mRNA-based medicines.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。